CME

Advancing Science in Residual Cardiovascular Risk: Will New Cardiovascular Outcomes Trials Bring a Paradigm Shift in Patient Care?

Advancing Science in Residual Cardiovascular Risk: Will New Cardiovascular Outcomes Trials Bring a Paradigm Shift in Patient Care?

This activity is supported by an unrestricted educational grant from Amarin Pharma, Inc.

Overview

CME Information

page 1 of 9